PT Tempo Scan Pacific Tbk (PEXXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PT Tempo Scan Pacific Tbk (PEXXF) trades at $0.09 with AI Score 47/100 (Grade C). PT Tempo Scan Pacific Tbk operates in the pharmaceuticals, personal care, and distribution sectors in Indonesia and internationally. Market cap: $463.12M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for PEXXF: PEXXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PEXXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PEXXF: the 1 perspectives are evenly split.
How is this calculated? →PT Tempo Scan Pacific Tbk (PEXXF) Healthcare & Pipeline Overview
PT Tempo Scan Pacific Tbk, an Indonesian-based company, manufactures and distributes pharmaceuticals, consumer products, and cosmetics, leveraging a strong brand portfolio including Bodrex and Marina, and a wide distribution network to serve both domestic and international markets within the healthcare and personal care sectors.
What Is the Investment Thesis for PEXXF?
PT Tempo Scan Pacific Tbk presents a compelling investment case based on its established market position, diverse product portfolio, and extensive distribution network. The company's attractive P/E ratio of 8.5 and a high dividend yield of 8.00% suggest potential value for investors. A profit margin of 11.0% and gross margin of 37.2% reflect solid profitability. Growth catalysts include expanding its product lines and penetrating new international markets. However, investors may want to evaluate the risks associated with operating in a competitive market and potential regulatory changes in the pharmaceutical and consumer goods industries. The company's beta of 0.60 indicates lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
PEXXF Key Highlights
- Market Cap of $463.12M indicates a mid-sized company with potential for growth.
- P/E ratio of 8.5 suggests the company may be undervalued compared to its earnings.
- Profit Margin of 11.0% demonstrates efficient operations and profitability.
- Gross Margin of 37.2% reflects the company's ability to manage production costs effectively.
- Dividend Yield of 8.00% provides a significant return for investors, indicating a commitment to shareholder value.
Who Are PEXXF's Competitors?
PEXXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AIHLF Adcock Ingram Holdings Limited | $3.50 | +0.00% | $624.32M | 48 |
| CCHWF Columbia Care Inc. | $0.94 | -21.71% | $521.35M | 41 |
| CKDXF Opthea Limited | $0.01 | +0.00% | $13.68M | 53 |
| DFHL Dong Fang Hui Le Inc. | $4.00 | -11.11% | $400.40M | 44 |
| ORRRY Orpea S.A. | $0.30 | -50.59% | $371.54M | 45 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PEXXF's Key Strengths?
- Strong brand recognition in Indonesia.
- Extensive distribution network.
- Diverse product portfolio.
- Established market position.
What Are PEXXF's Weaknesses?
- Dependence on the Indonesian market.
- Limited international presence compared to global competitors.
- Potential vulnerability to regulatory changes.
- Exposure to currency fluctuations.
What Could Drive PEXXF Stock Higher?
- Potential new product launches in the pharmaceutical and consumer goods segments within the next 12-18 months.
- Expansion of distribution network in Southeast Asia to increase market reach.
- Investments in research and development to drive innovation and product differentiation.
- Potential partnerships with e-commerce platforms to boost online sales.
- Government initiatives to improve healthcare access in Indonesia.
What Are the Key Risks for PEXXF?
- Increasing competition from local and international players in the pharmaceutical and consumer goods industries.
- Regulatory changes in the pharmaceutical and consumer goods sectors that could impact profitability.
- Economic downturns in Indonesia and other key markets that could reduce consumer spending.
- Currency fluctuations that could affect the company's financial performance.
- Risks associated with operating in the OTC market, including limited liquidity and disclosure.
What Are the Growth Opportunities for PEXXF?
- Expanding Product Lines: PT Tempo Scan Pacific Tbk has the opportunity to expand its product lines within the pharmaceutical and consumer goods segments. By investing in research and development, the company can introduce new products that cater to evolving consumer needs and preferences. The market for innovative healthcare and personal care products is growing, presenting a significant opportunity for PT Tempo Scan Pacific Tbk to increase its market share. This expansion can be achieved within the next 2-3 years with sufficient investment in R&D.
- Penetrating New International Markets: PT Tempo Scan Pacific Tbk can leverage its existing distribution network to penetrate new international markets. Southeast Asia, in particular, offers significant growth potential due to its large population and increasing demand for healthcare and consumer goods. By tailoring its products to local preferences and establishing strategic partnerships, the company can successfully expand its international presence. This expansion could begin within the next year, focusing initially on neighboring countries.
- Leveraging E-commerce Platforms: The increasing adoption of e-commerce in Indonesia and other Southeast Asian countries presents a significant growth opportunity for PT Tempo Scan Pacific Tbk. By partnering with leading e-commerce platforms and developing its own online sales channels, the company can reach a wider customer base and increase its sales. The e-commerce market in Indonesia is projected to grow significantly in the coming years, making this a strategic area for investment. This initiative can be implemented within the next 6-12 months.
- Focusing on Herbal and Natural Products: With growing consumer interest in natural and herbal products, PT Tempo Scan Pacific Tbk can capitalize on this trend by expanding its range of herbal and natural remedies. By leveraging its existing brands and distribution network, the company can effectively market these products to health-conscious consumers. The market for herbal and natural products is expanding rapidly, presenting a significant opportunity for PT Tempo Scan Pacific Tbk to increase its market share. This can be achieved through targeted marketing campaigns and product development over the next 1-2 years.
- Strengthening Distribution Network: PT Tempo Scan Pacific Tbk can further strengthen its distribution network by investing in logistics and infrastructure. By improving its supply chain efficiency and expanding its distribution reach, the company can ensure that its products are readily available to customers across Indonesia and other markets. A robust distribution network is crucial for maintaining a competitive edge in the consumer goods and pharmaceutical industries. This ongoing effort will solidify the company's market position.
What Opportunities Does PEXXF Have?
- Expanding into new international markets.
- Developing new products and formulations.
- Leveraging e-commerce platforms.
- Capitalizing on the growing demand for herbal and natural products.
What Threats Does PEXXF Face?
- Increasing competition from local and international players.
- Changing consumer preferences.
- Economic downturns in Indonesia and other markets.
- Regulatory challenges and compliance costs.
What Are PEXXF's Competitive Advantages?
- Strong brand recognition in Indonesia and other markets.
- Extensive distribution network across Indonesia.
- Diverse product portfolio spanning pharmaceuticals, personal care, and cosmetics.
- Established relationships with retailers and distributors.
What Does PEXXF Do?
PT Tempo Scan Pacific Tbk, founded in 1970 and headquartered in Jakarta, Indonesia, has evolved into a prominent player in the pharmaceuticals, personal care, and distribution services industries. Originally known as PT Scanchemie, the company has grown into a diverse conglomerate with a significant presence in Indonesia and internationally. Its operations are divided into three main segments: Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services. The Pharmaceuticals segment focuses on the manufacturing and trading of pharmaceutical products and medical devices. The Consumer Products and Cosmetics segment produces a wide range of personal care items, cosmetics, and household products. These products are sold under well-known brands such as Bodrex, Oskadon, Marina, and MY BABY. The Distribution Services segment supports the company's operations through warehousing, freight forwarding, and marketing activities. PT Tempo Scan Pacific Tbk is a subsidiary of PT Bogamulia Nagadi, which provides a stable ownership structure. The company's commitment to research and development, combined with its extensive distribution network, positions it as a key player in the Indonesian market.
What Products and Services Does PEXXF Offer?
- Manufactures and trades pharmaceutical products and medical devices.
- Produces and distributes personal care items, cosmetics, and household products.
- Sells products under brands like Bodrex, Marina, and MY BABY.
- Provides warehousing and freight forwarding services.
- Engages in advertising and promotion activities.
- Conducts research and development for new products and formulations.
- Offers information technology and communication network systems services.
- Procures, distributes, and markets products.
How Does PEXXF Make Money?
- Manufacturing and selling pharmaceutical products and medical devices.
- Producing and distributing consumer products, cosmetics, and household items.
- Providing distribution and logistics services to support its operations.
- Generating revenue through a diverse portfolio of brands and products.
What Industry Does PEXXF Operate In?
PT Tempo Scan Pacific Tbk operates in the competitive pharmaceutical and consumer goods industries in Indonesia and internationally. The Indonesian pharmaceutical market is experiencing growth driven by increasing healthcare awareness and government initiatives to improve access to healthcare. The consumer goods sector is also expanding due to rising disposable incomes and changing consumer preferences. PT Tempo Scan Pacific Tbk competes with both local and international players, including AIHLF, CCHWF, CKDXF, DFHL, and ORRRY. The company's established brands and distribution network provide a competitive advantage in this dynamic market.
Who Are PEXXF's Key Customers?
- Consumers in Indonesia and international markets.
- Retailers and distributors who sell PT Tempo Scan Pacific Tbk's products.
- Hospitals and clinics that use the company's pharmaceutical products.
- E-commerce platforms and online retailers.
PEXXF Valuation & Market Position
With a $463.12M market cap, PT Tempo Scan Pacific Tbk sits in the small-cap segment of the market. Relative to its peer group, PEXXF's quantitative score of 47/100 is roughly in line with the peer average of 46/100.
ROE 15%Key Financial Metrics
Return on equity for PT Tempo Scan Pacific Tbk stands at 14.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.1%, showing how much profit it generates from its asset base. PEXXF trades at a trailing price-to-earnings ratio of 8.46, below the Healthcare sector average of ~23x. Its free cash flow yield is 10.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 12.2%, the inverse of the P/E and a quick read on earnings relative to price.
PEXXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Tempo Scan's insider activity suggests confidence in the company's direction. Recent buys could signal positive expectations for future performance.
- Community sentiment indicates a growing belief in the company's long-term strategy. Discussions highlight potential for market share expansion.
- Positive community views focus on Tempo Scan's established brand reputation. The company's history and market presence are seen as strengths.
- Market perception acknowledges Tempo Scan's resilience in a competitive sector. Recent developments are viewed as supportive of continued growth.
Bear Case
- Recent insider selling activity could indicate concerns about short-term prospects. Some see this as a potential red flag.
- Community sentiment reveals worries about increasing competition. Discussions mention potential margin pressure from new market entrants.
- Bearish community views highlight concerns about regulatory changes. Potential impacts on Tempo Scan's operations are being debated.
- Market perception acknowledges challenges in the current economic climate. Developments are viewed as potentially hindering Tempo Scan's progress.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PEXXF Latest News
No recent news available for PEXXF.
PEXXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PEXXF.
Price Targets
Wall Street price target analysis for PEXXF.
PEXXF MoonshotScore
What does this score mean?
The MoonshotScore rates PEXXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: I Made Dharma Wijaya
CEO
I Made Dharma Wijaya serves as the CEO of PT Tempo Scan Pacific Tbk, leading a large workforce of 4545 employees. His background encompasses extensive experience in the consumer goods and pharmaceutical industries. He has held various leadership positions within PT Tempo Scan Pacific Tbk, contributing to the company's strategic planning and operational efficiency. His expertise includes market analysis, product development, and distribution management. He is committed to driving innovation and growth within the company.
Track Record: Under I Made Dharma Wijaya's leadership, PT Tempo Scan Pacific Tbk has maintained its strong market position and expanded its product portfolio. He has overseen the implementation of key strategic initiatives, including investments in research and development and the expansion of the company's distribution network. His focus on operational excellence has contributed to improved profitability and efficiency. He has also played a key role in fostering a culture of innovation and collaboration within the company.
PEXXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PT Tempo Scan Pacific Tbk may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Higher risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- Established operating history since 1970.
- Presence in the pharmaceutical and consumer goods industries.
- Recognizable brands such as Bodrex and Marina.
- Subsidiary of PT Bogamulia Nagadi.
- Employs a large workforce of 4545 employees.
What Investors Ask About PT Tempo Scan Pacific Tbk (PEXXF) — Healthcare
What does PT Tempo Scan Pacific Tbk do?
PT Tempo Scan Pacific Tbk is a diversified company that manufactures, markets, and distributes a wide range of pharmaceutical and consumer products. Its pharmaceutical division produces over-the-counter medications and prescription drugs, while its consumer products division offers personal care, cosmetics, and household items under well-known brands like Bodrex and Marina. The company's extensive distribution network ensures its products reach consumers across Indonesia and in select international markets, making it a key player in the Indonesian healthcare and consumer goods landscape.
What do analysts say about PEXXF stock?
Analyst coverage for PEXXF may be limited due to its OTC listing. However, key valuation metrics such as its P/E ratio of 8.5 and dividend yield of 8.00% could be considered attractive. Growth considerations include the company's ability to expand its product lines, penetrate new markets, and leverage e-commerce platforms. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. Analyst consensus is Unknown.
What are the main risks for PEXXF?
The main risks for PT Tempo Scan Pacific Tbk include increasing competition in the pharmaceutical and consumer goods industries, potential regulatory changes, and economic downturns in Indonesia and other key markets. As an OTC-listed company, PEXXF also faces risks related to limited liquidity and disclosure. Currency fluctuations could also impact the company's financial performance. Investors should carefully consider these risks before investing in PEXXF.
What are the key factors to evaluate for PEXXF?
PT Tempo Scan Pacific Tbk (PEXXF) holds an AI score of 47/100 (low). P/E: 8.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does PEXXF data refresh on this page?
PEXXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PEXXF's recent stock price performance?
PT Tempo Scan Pacific Tbk (PEXXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition in Indonesia. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PEXXF overvalued or undervalued right now?
PT Tempo Scan Pacific Tbk (PEXXF) trades at 8.5x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PEXXF?
Before investing in PT Tempo Scan Pacific Tbk (PEXXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for PEXXF due to its OTC listing.
- Financial data based on available information and may not be fully comprehensive.